Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

DANSK FARMACEUTISK INDUSTRI A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Bankruptcy risk for industry   3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7%   Bankruptcy risk   0.7% 0.8% 0.9% 0.9% 1.1% 1.5% 10.3% 10.3%   Credit score (0-100)   96 92 88 89 85 75 24 24   Credit rating   AA AA A A A A BB BB   Credit limit (kDKK)   1,539.5 1,273.6 1,890.1 1,420.2 826.3 79.2 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   12,855 11,420 20,799 15,591 12,266 18,406 0.0 0.0   EBITDA   8,803 7,519 17,243 10,876 6,663 14,850 0.0 0.0   EBIT   8,390 7,009 16,903 10,660 6,488 14,708 0.0 0.0   Pre-tax profit (PTP)   8,460.2 7,030.4 16,810.1 9,391.3 6,190.1 14,345.1 0.0 0.0   Net earnings   6,596.6 5,481.9 13,108.5 7,316.4 4,821.9 11,185.8 0.0 0.0   Pre-tax profit without non-rec. items   8,460 7,030 16,810 9,391 6,190 14,345 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Tangible assets total   1,506 1,880 1,155 353 178 36.4 0.0 0.0   Shareholders equity total   10,127 9,009 16,618 10,634 7,456 13,642 1,242 1,242   Interest-bearing liabilities   7,056 13,118 11,839 29,128 31,276 915 0.0 0.0   Balance sheet total (assets)   22,898 28,946 35,811 45,831 49,810 23,744 1,242 1,242   Net Debt   5,649 10,180 10,727 26,735 19,216 915 -1,242 -1,242     See the entire balance sheet 1000.0 Volume  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   12,855 11,420 20,799 15,591 12,266 18,406 0.0 0.0   Gross profit growth   5.9% -11.2% 82.1% -25.0% -21.3% 50.1% -100.0% 0.0%   Employees   8 8 7 7 7 7 0 0   Employee growth %   0.0% 0.0% -12.5% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   22,898 28,946 35,811 45,831 49,810 23,744 1,242 1,242   Balance sheet change%   18.0% 26.4% 23.7% 28.0% 8.7% -52.3% -94.8% 0.0%   Added value   8,803.2 7,519.0 17,243.3 10,875.6 6,703.7 14,850.1 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -793 -136 -1,065 -1,018 -350 -283 -36 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   65.3% 61.4% 81.3% 68.4% 52.9% 79.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   40.1% 27.4% 52.4% 26.6% 16.4% 46.5% 0.0% 0.0%   ROI %   53.3% 36.0% 66.6% 31.7% 19.9% 64.2% 0.0% 0.0%   ROE %   68.2% 57.3% 102.3% 53.7% 53.3% 106.0% 0.0% 0.0%   1000.0 Solidity  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Equity ratio %   44.2% 31.1% 46.4% 23.2% 15.0% 57.5% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   64.2% 135.4% 62.2% 245.8% 288.4% 6.2% 0.0% 0.0%   Gearing %   69.7% 145.6% 71.2% 273.9% 419.5% 6.7% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.2% 0.8% 1.2% 7.1% 5.4% 17.1% 0.0% 0.0%   1000.0 Liquidity  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Quick Ratio   1.1 1.0 1.7 1.0 0.9 2.0 0.0 0.0   Current Ratio   1.9 1.4 2.2 1.4 1.2 3.3 0.0 0.0   Cash and cash equivalent   1,407.8 2,937.6 1,111.7 2,392.7 12,059.6 0.0 0.0 0.0   1000.0 Capital use efficiency  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   9,445.9 7,344.8 18,672.5 9,632.8 6,996.7 16,137.1 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023 2024/6 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   1,100 940 2,463 1,554 958 2,121 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   1,100 940 2,463 1,554 952 2,121 0 0   EBIT / employee   1,049 876 2,415 1,523 927 2,101 0 0   Net earnings / employee   825 685 1,873 1,045 689 1,598 0 0